Business context and reporting period
The supplied filing is Mind Medicine (MindMed) Inc.’s unaudited Form 10-Q for the quarter and nine months ended September 30, 2023, filed November 2, 2023. This does not match the request metadata naming Definium Therapeutics, Inc.; the summary below reflects the filing provided. MindMed is a clinical-stage biopharmaceutical company developing brain-health treatments, including lead candidates MM-120 and MM-402. It reported no revenue.
Financial results and liquidity
Amounts are in U.S. dollars; financial statement amounts are in millions unless otherwise indicated.
| Metric | Q3 2023 | Q3 2022 | Nine months 2023 | Nine months 2022 |
|---|---|---|---|---|
| Revenue | None reported | None reported | None reported | None reported |
| Research and development expense | $13.2 | $7.8 | $40.6 | $27.3 |
| General and administrative expense | $8.4 | $9.2 | $31.1 | $25.1 |
| Net loss | $17.9 | $16.5 | $71.9 | $51.9 |
| Net loss per share | $0.45 | $0.56 | $1.85 | $1.82 |
| Operating cash used | Not provided quarterly | Not provided quarterly | $43.8 | $37.3 |
At September 30, cash and cash equivalents were $117.7 million, working capital was $88.9 million, total assets were $141.6 million, total liabilities were $45.6 million, and shareholders’ equity was $96.0 million. Cash declined $24.4 million from year-end 2022. Management said current cash was expected to fund operations into 2026, while cautioning that this estimate depends on assumptions and may change. No operating margin is meaningful given the absence of revenue; the company reported operating losses.
In August 2023, MindMed borrowed $15.0 million under a credit facility that permits up to $50.0 million in total loans, including milestone-dependent and lender-discretionary tranches. The facility bears variable interest at the greater of 10.95% or prime plus 2.95%, matures August 2027, and is secured by substantially all assets except intellectual property. $14.1 million was reported as long-term debt, net of issuance costs. The company also had $13.5 million of warrant liability and approximately $29.4 million of future contractual commitments, most of which it said are cancellable with notice.
Material changes versus prior comparable periods
- Quarterly R&D expense rose 70%; nine-month R&D rose 48%, chiefly because of higher MM-120 GAD study and product-development costs.
- Quarterly G&A expense decreased 9%, while nine-month G&A increased 24%; the filing attributes the latter increase mainly to proxy-contest-related professional fees and costs of business growth.
- Nine-month net loss increased 38% and operating cash use increased from $37.3 million to $43.8 million.
- Interest income increased with higher interest rates. Warrant revaluation produced a $3.0 million gain in Q3 but a $3.7 million loss for the nine-month period.
- Cash was down from $142.1 million at December 31, 2022; the company raised $5.0 million net through its ATM during the first nine months and received $15.0 million from the new credit facility.
Outlook, commentary, risks and unusual items
- MindMed completed enrollment of 198 participants in the MM-120 Phase 2b GAD study. It expected four-week topline results in Q4 2023 and twelve-week results by the end of Q1 2024. These were expectations stated in the filing, not reported results.
- The company reported positive topline results from a collaborator’s investigator-initiated lysergide MDD study. Its high-dose group showed greater improvement on the primary measure than the lower-dose control; MindMed cautioned that its own product candidate remains investigational.
- In October 2023, after the quarter end, MindMed announced completion of enrollment in its 53-patient MM-120 ADHD Phase 2a study and expected topline results by the end of Q1 2024.
- The company expects R&D spending to rise as development progresses. It has not generated revenue and expects continued losses, and may need additional capital; financing may dilute shareholders or restrict operations. MM-110 development remained paused pending non-dilutive funding or collaboration.
- Credit-agreement covenants restrict certain activities, and an event of default could make obligations immediately payable. The company said it was in compliance at September 30, 2023.
- MindMed disclosed two lawsuits it filed against Dr. Scott Freeman and others relating to alleged breaches of a separation agreement and alleged proxy-filing violations. It reported no other material litigation likely to have a material adverse effect, in management’s view.
- Management concluded disclosure controls were effective at a reasonable assurance level and reported no material quarter-period change in internal control over financial reporting.
Important facts for investors to verify
- Confirm the issuer: the request metadata says Definium Therapeutics, while the supplied 10-Q is for Mind Medicine (MindMed) Inc.
- Verify subsequent MM-120 GAD and ADHD trial results against the stated timelines and distinguish company-sponsored trials from collaborator-led research.
- Assess the cash-runway estimate against actual spending, future trial costs, debt interest and access to additional financing.
- Review the loan’s milestone conditions, covenants, collateral, default provisions and availability of undrawn tranches.
- Reconcile ATM share-sale figures: the filing’s equity statement and note report 800,700 shares in Q3 and 1,402,598 for nine months, while MD&A reports 787,500 and 1,389,398, respectively. Net proceeds are reported as approximately $3.1 million and $5.0 million.
- Consider potential dilution: the filing reports 40,094,708 common shares outstanding at September 30 and 53,297,712 common-share equivalents on a fully converted basis.